Literature DB >> 8221048

Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis.

D H Miller1, F Barkhof, J J Nauta.   

Abstract

There is now widespread agreement that serial brain MRI is useful in monitoring treatments designed to modify the course of multiple sclerosis. It has been less clear whether gadolinium enhancement is needed. We therefore compared the relative sensitivity of long repetition time (TR) spin echo (SE) and gadolinium enhanced short TR SE sequences in detecting active lesions. A blind analysis of the two sequences was performed in 26 untreated patients with early relapsing--remitting (19) or secondary progressive (seven) multiple sclerosis who underwent monthly MRI on four occasions (one baseline and three follow-up). Active lesions were defined as either new or enlarged lesions on long TR SE, or new or persistent enhancing lesions on short TR SE. In one patient there were 144 active lesions, all of which were seen with enhancement on short TR SE, but only 17 were seen on long TR SE. Amongst the remaining 25 cases, a total of 106 active lesions were seen: 68 (64%) were seen only with enhancement on short TR SE, 16 (15%) were seen only on long TR SE, while 22 (21%) were active on both sequences. We conclude that gadolinium enhancement markedly increases the sensitivity of monthly brain MRI in monitoring the treatment of relapsing--remitting or secondary progressive multiple sclerosis. With this frequency of scanning, a post contrast short TR SE sequence is the most sensitive method for detecting active lesions. The smaller yet still substantial incidence of active lesions seen only on the long TR SE sequence suggests that it should also be obtained.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221048     DOI: 10.1093/brain/116.5.1077

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  38 in total

1.  Predictive value of lesions for relapses in relapsing-remitting multiple sclerosis.

Authors:  J A Koziol; S Wagner; D F Sobel; L S Slivka; J S Romine; J C Sipe; H P Adams
Journal:  AJNR Am J Neuroradiol       Date:  2001-02       Impact factor: 3.825

2.  Magnetisation transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosis.

Authors:  M Cercignani; M Bozzali; G Iannucci; G Comi; M Filippi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-03       Impact factor: 10.154

3.  ["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients].

Authors:  C Krogias; A Schröder; H Wiendl; R Hohlfeld; R Gold
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

Review 4.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 5.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

6.  Supervised automatic procedure to identify new lesions in brain MR longitudinal studies of patients with multiple sclerosis.

Authors:  R C Parodi; F Levrero; M P Sormani; A Pilot; G L Mancardi; A Aliprandi; F Sardanelli
Journal:  Radiol Med       Date:  2008-04-02       Impact factor: 3.469

7.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

8.  High-dose contrast-enhanced MRI in multiple sclerosis.

Authors:  T Koudriavtseva; C Pozzilli; C Di Biasi; M Iannilli; G Trasimeni; C Gasperini; C Argentino; G F Gualdi
Journal:  Neuroradiology       Date:  1996-05       Impact factor: 2.804

Review 9.  Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.

Authors:  J H Simon
Journal:  West J Med       Date:  1996-06

10.  The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis.

Authors:  Deeya Gaindh; Neal Jeffries; Joan Ohayon; Nancy D Richert; Clelia Pellicano; Joseph A Frank; Henry McFarland; Francesca Bagnato
Journal:  Expert Opin Biol Ther       Date:  2008-12       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.